Aardvark Therapeutics Reports Increased Operating Expenses and Net Losses in Q1 2026

Aardvark Therapeutics, Inc. reported a significant increase in operating expenses and net losses for the first quarter of 2026, as detailed in its latest 10-Q filing. The company recorded total operating expenses of $22.5 million, up from $10.5 million in the same period last year, marking a 115% increase. This rise was primarily driven by a substantial increase in research and development (R&D) expenses, which reached $16.6 million compared to $7.8 million in the prior year. The net loss for the quarter was $21.6 million, compared to a loss of $9.3 million in the first quarter of 2025, resulting in a net loss per share of $0.99, up from $0.71.

In terms of financial position, Aardvark's total assets decreased to $98.6 million as of March 31, 2026, down from $117.2 million at the end of 2025. The decline was attributed to a reduction in cash and cash equivalents, which increased to $62.4 million from $47.1 million, while short-term investments fell significantly from $63.0 million to $28.8 million. The company's accumulated deficit also widened to $137.5 million, reflecting ongoing investments in its clinical programs without any revenue generation.

Strategically, Aardvark has been focusing on its lead product candidate, ARD-101, which is currently in clinical trials for treating hyperphagia associated with Prader-Willi Syndrome (PWS). However, in February 2026, the company voluntarily paused enrollment and dosing in its Phase 3 HERO trial and related studies due to safety observations in a healthy volunteer study. This pause may impact the timeline for future clinical developments and the company's overall strategy. Aardvark has also expanded its clinical management and regulatory capabilities, hiring additional personnel to support its operations.

Operationally, Aardvark's workforce has grown, with an increase in personnel-related costs contributing to the rise in general and administrative expenses, which totaled $5.9 million for the quarter. The company has not generated any revenue to date and continues to rely on external funding to support its operations. As of March 31, 2026, Aardvark had cash, cash equivalents, and short-term investments totaling $91.2 million, which it believes will be sufficient to fund operations into mid-2027. However, the company anticipates needing additional capital to continue its development efforts and is exploring various financing options, including equity offerings and collaborations.

Looking ahead, Aardvark's management expects operating losses to increase as the company continues its clinical trials and research activities. The outcome of the ongoing review of its clinical programs and discussions with the FDA will be critical in determining the future direction of its product candidates and overall business strategy. The company remains committed to advancing its pipeline of novel therapeutics targeting metabolic diseases, despite the challenges posed by the recent clinical trial pauses.